Results of a Phase III trial on CT-P6, a trastuzumab biosimilar candidate, in early breast cancer

Justin Stebbing, MD, PhD from Imperial College Healthcare NHS Trust, UK, presents results from a double-blind phase III study comparing the efficacy and safety of CT-P6, a trastuzumab biosimilar candidate, versus traztuzumab as neoadjuvant treatment in HER2-postivie early breast cancer.
Share this video